Abstract
Good Manufacturing Practice (GMP) and the need for product improvement became a major issue in blood transfusion in many western countries in the late 60s. This was most evident in the United States where a centralized agency, the Food and Drug Administration (FDA), was empowered to control not only the manufacturers of drugs but also blood banks and the manufacturers of products originating from human blood and its components. Today, most countries have created such agencies which control (more or less intensively) the activities of blood banks and fractionation facilities. This appears to be related to several factors:
-
1.
An ever increasing number of safety tests that have to be performed, implying that the possibility of errors also increases.
-
2.
The increasing complexity of technology and equipment
-
3.
A shortage of appropriately trained laboratory personnel in some countries.
-
4.
The development of new products for diseases for which no, or only limited, treatments exist.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
List of selected references, guidelines and governmental rules
General references
Bartlett R. Leadership for quality. ASM News 1991;57:15–21.
DeBoy J, Jarboe B. Government-mandated cytology proficiency testing: Practical, equitable and defensible standards. ORB 1991:152–61.
Juran, J. Quality control handbook. McGraw-Hill, New York NY,1974.
Kritchevsky S,. Simmons B. Continuous quality improvement: Concepts and applications for physician care. JAMA 1991;266:1817–23.
Milakovich ME. Creating a total quality health care environment. Health Care Manage Rev 1991;16(2):9–20.
McLaughlin CP, Kaluzny AD. Total quality management in health: Making it work. Health Care Manage Rev 1990;15(3):7–14.
Rosvoll R (ed). Accreditation requirements manual of the American Association of Blood Banks. American Association of Blood Banks, Arlington VA 1990.
Walker R (ed). Technical manual. American Association of Blood Banks, Arlington VA 1990.
Julius C, Westphal RG. The safety of blood components and derivatives. Hematology/Oncology Clinics of North America 1992;6(5): 1057–77.
b. Documents issued by the Council of Europe, Health Division, F-67075 Strasbourg Cedex France
Recommendation No. R(86)6. Guidelines for the preparation, quality control and use of fresh frozen plasma (FFP), 1986.
Recommendation No. R(88)4. Responsibilities of health authorities in the field of blood transfusion, 1988.
Recommendation No. R(90)9 + Report. Plasma products and European selfsufficiency, 1990.
Guide to preparation, use and quality assurance of blood components, 1991.
c. Documents issued by the Commission of the European Community, Rue de la Loi 200, B-1049 Bruxelles, Belgium
The rules governing medicinal products for human use in the European Community. Volume I. Catalogue number CO-71–91–631-EN-C.
Notice to applicants for marketing authorisations for medicinal products for human use in the Member States of the Community. Volume II. Catalogue number CB-55–89–293-EN-C.
Guidelines on the quality, safety and efficacy of medicinal products for human use. Volume III. Catalogue number CB-55–89–843-EN-C.
Addendum (July 1990) CB-59–90–936-EN-C.
Addendum No. 2 (May 1992) CO-75–92–558-EN-C.
Good Manufacturing Practice for medical products. Volume IV. Catalogue number CO-71–91–760-EN-C.
Council directive 89/381/EEC of 14 June 1989, extending the scope of Directives 65/65/EEC and 75/319/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products and laying down special provisions for medicinal products derived from human blood and human plasma (O.J. No. L181 of 28.6.89).
Note for Guidance. Medicinal products derived from human blood and plasma in Volume III of the rules governing medicinal products in the European Community, addendum No. 2. Catalogue number CO-75–92–558-EN-C.
Note for Guidance. Validation of virus removal and inactivation procedures in Volume III of the rules governing medicinal products in the European Community, addendum No. 2. Catalogue number CO-75–92–558-EN-C.
111/3232/92. Manufacture of products derived from human blood or human plasma, Annex to the EC guide to the GMP.
d. Selected Documents issued by the World Health Organization, WHO, 20, Ave Appia, CH-1211 Geneva, Switzerland
Lab/89.5. Minimum targets for blood transfusion services. (Available in English, French, Spanish).
Lab/89.6. Consensus statement on accelerated strategies to reduce the risk of transmission of HIV by blood transfusion. (Available in English, French, Spanish).
Lab/89.7. Essential blood components, plasma derivatives and substitutes. (Available in English, French, Spanish).
Lab/89.8. Essential consumables and equipment of a blood transfusion service. (Available in English, French, Spanish).
Lab/89.9. Use of plasma substitutes and plasma in developing countries. (Available in English, French, Spanish).
Lab/89.10. Guidelines for the appropriate use of blood. (Available in English, French, Spanish).
WHO, 1990. ISBN92–4–154406–6. Management of Blood Transfusion Services.
LBS/91.1. Consensus statement on screening of blood donations for infectious agents transmissible through blood transfusion. (Available in English, French, Spanish).
WHO, 1992. Guidelines for the organization of a blood transfusion service.
WHO/LBS/92.5. Viral inactivation of blood and blood products, by Dr H Suomela, Finland.
WHO/LBS/92.6. Report of the GBSI Informal Consultation on “Assessment of training needs in transfusion medicine”.
WHO/LBS/92.7. Report of the GBSI Informal Consultation on “Costing of blood transfusion services”.
WHO, 1993. Guidelines for quality assurance programs for blood transfusion services.
Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. (A revised edition will be published in 1993).
e. Documents issued by the US Health and Human Services, Food and Drug Ad- ministration, Center of Biologies Evaluation and Research (HFM-635), 8800 Rock- ville Pike, Bethesda, BD 20892
Title 21, Code of Federal Regulations, Parts 210, 211, 600, 606, 610, 640, 660.
Center for Drugs and Biologies and Center for Devices and Radiological Health (CDRH), Guideline on general principles of process validation (May 1987).
FDA 91-4179. CDRH, Medical device good manufacturing practices manual, 56th edition (August 1991).
FDA Compliance program guidance manual, blood and blood products, 7342–001 (1992), 7342.002 (1991).
FDA Compliance policy guide, FDA access to results of quality assurance program audits and inspections, 7151.02 (1989).
FDA Memorandum. April 6, 1988, Control of unsuitable blood and blood products.
FDA Memorandum. March 20, 1991, Deficiencies relating to the manufacture of blood and blood components.
Federal Register, Volume 43, No. 190, Friday, September 29, 1978. Human and veterinary drugs, current good manufacturing practice in manufacture, processing, packing, or holding, 45013–45087.
Federal Register, Volume 40, No. 223, Tuesday, November 18, 1975. Human blood and blood products, collection, storage and processing, 53532–53544.
Federal Register, Volume 57, No. 40, Friday, February 28, 1992. Clinical laboratory improvement amendments of 1988, Final Rule, 7002–7288.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Heiniger, H.J. (1994). State of the Art and Future Directions a Brief Overview. In: Sibinga, C.T.S., Das, P.C., Heiniger, H.J. (eds) Good Manufacturing Practice in Transfusion Medicine. Developments in Hematology and Immunology, vol 29. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2608-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2608-7_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6117-6
Online ISBN: 978-1-4615-2608-7
eBook Packages: Springer Book Archive